<DOC>
	<DOCNO>NCT00131274</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Gleevec ( imatinib mesylate ) treatment idiopathic pulmonary fibrosis ( IPF ) .</brief_summary>
	<brief_title>Gleevec Idiopathic Pulmonary Fibrosis ( IPF ) Study</brief_title>
	<detailed_description>This multicenter , double-blind , parallel , placebo-controlled , randomized phase 2 study evaluate safety efficacy Gleevec ( imatinib mesylate ) treatment Idiopathic Pulmonary Fibrosis ( IPF ) . One-hundred- twenty patient enrol trial total . Subjects must diagnosis make HRCT show definite probable IPF clinical symptom consistent IPF onset 3 36 month prior screen . Subjects randomly assign receive either Gleevec 600 mg orally placebo , per day approximately 2 year . The primary efficacy progression define great 10 % decline force vital capacity death . Measures safety include randomize patient receive least one dose study medication . All adverse event serious adverse event separately tabulate mapped standard classification system group body system . Any serious adverse event occur trial 30 day end therapy report FDA within 24 hour follow outcome .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Clinical symptom consistent IPF onset 3 month 36 month prior screen Worsening demonstrated one follow within past year : 1 . &gt; 10 % decrease FVC % predict , 2 . Worsening chest xray 3 . Worsening dyspnea rest exertion Age 20 â€“79 year age . Subjects aged 2050 must diagnosis either open videoassisted thoracic surgery ( VATS ) lung biopsy Diagnosis must make ( HRCT ) show definite probable IPF AND either follow : 1 . Open VATS lung biopsy show definite probable usual interstitial pneumonitis ( UIP ) 2 . Nondiagnostic transbronchial biopsy exclude condition ( include granulomatous disease malignancy ) AND abnormal pulmonary function test ( reduce FVC decrease DLCO impair gas exchange rest exercise ) AND 2 following : 1 . Age &gt; 50 year 2 . Insidious onset otherwise unexplained dyspnea exertion 3 . Bibasilar , inspiratory crackle examination FVC &gt; 55 % predict value baseline DLCO &gt; 35 % predict value screen PaO2 &gt; 60 mmHg ( sea level ) 55 mmHg ( altitude ) rest room air Able understand willing provide inform consent prior study procedure History clinically significant environmental exposure know cause pulmonary fibrosis Diagnosis connective tissue disease FEV1/FVC ratio &lt; 0.6 screening ( postbronchodilator ) Residual volume &gt; 120 % predict screening Evidence active infection Any condition IPF , , opinion site principal investigator , likely result death patient within next year History unstable deteriorate cardiac neurologic disease Women child bear potential Current treatment corticosteroid , cytoxan , azathioprine , colchicine , pirfenidone , interferon gamma beta , antitumor necrosis factor therapy endothelin receptor blocker .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Pulmonary Fibrosis</keyword>
	<keyword>Respiratory Diseases</keyword>
	<keyword>Interstitial Lung Disease</keyword>
	<keyword>Usual Interstitial Pneumonia</keyword>
</DOC>